ALK and inflammatory myofibroblastic tumor: Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring <i>ALK-IGFBP5</i> fusion.